Abstract 1741P
Background
Little research has been made on real-world clinical scenarios of potential ethical relevance in specific cancers, including sarcomas.
Methods
Our sarcoma multidisciplinary tumor board (MTB) discusses all cases of adult patients with soft tissue sarcomas, bone sarcomas and GIST selected by the clinical oncologist in charge as deserving a multidisciplinary discussion. Over a 1-yr interval, all discussed cases were filtered by a group of senior and junior experts in bioethics and sarcomas in order to highlight those of potential ethical concern, i.e. whenever a problematic conflict could be envisaged between the ethical principles of beneficence, non-maleficence, autonomy and justice. These cases were retrospectively reviewed, and an attempt was made to group them into distinct ethical scenarios.
Results
From January to December 2023, 327 sarcoma cases were discussed by our MTB. Forty-one cases (12%) were prospectively or retrospectively selected as carrying possible ethical relevance. Among them, the following clinical scenarios were identified (total >100% since scenarios are not mutually exclusive): 1. ethically-relevant uncertainty about a diagnostic/treatment option (46%); 2. best treatment option at a high-risk of complications of problematic acceptance (5%); 3. controversial futility (17%); 4. problematic trade-off between quality and quantity of life (17%); 5. problematic management of patient dissent (15%); 6. clinical disagreement of potential ethical concern (10%); 7. problematic communication of all clinical implications to the individual patient (15%). 8. controversial enrolment of an eligible patient in a clinical trial or trial requirements of ethical concern in the individual patient (2%); 9. best clinical option conflicting with social/economical constraints (0.3%); 10. bedside rationing, or perception of implicit rationing of scarce resources (2%).
Conclusions
A non-negligible incidence of ethically-relevant clinical cases was observed. Sarcoma centres should be aware of specific ethical implications possibly affecting their everyday practice. Paradigmatic clinical cases for each of the ten clinical scenarios proposed herein will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1382P - Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
Presenter: Maurice Pérol
Session: Poster session 06
1383P - Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based study
Presenter: Dongmei Lin
Session: Poster session 06
1384P - Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Yuki Sato
Session: Poster session 06
1385P - Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma
Presenter: Mariana Mancini
Session: Poster session 06
1386P - Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKI
Presenter: Wei Xin Zhao
Session: Poster session 06
1387P - Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK
Presenter: Rubab Batool
Session: Poster session 06
1388P - Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster session 06
Resources:
Abstract
1389P - Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease
Presenter: Siddhartha Goutam
Session: Poster session 06
1390P - Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
Presenter: Inès Duparc
Session: Poster session 06